The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Trasicor     1-(propan-2-ylamino)-3-(2- prop-2...

Synonyms: Trasacor, Coretal, Koretal, Laracor, Tevacor, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Coretal


Psychiatry related information on Coretal


High impact information on Coretal


Chemical compound and disease context of Coretal


Biological context of Coretal


Anatomical context of Coretal

  • As in CHO-beta 3 cells, the classical beta 1- and beta 2-antagonists CGP12177, oxprenolol, and pindolol were partial agonists in adipocytes [20].
  • This was achieved by determining: 1) the effect of oxprenolol (0.3 mg/kg), a potent beta receptor blocking agent possessing no significant direct membrane effects on the myocardium, on the dose of ouabain necessary to cause VT (i.e., the toxic dose); and 2) whether oxprenolol had antirrhythmic efficacy against preexisting VT [21].
  • Our results suggest that enantioselective interactions of the chiral oxprenolol with the chiral lipids of biological membranes can be excluded [22].
  • The intrinsic activities of alprenolol, oxprenolol and pindolol (expressed as % of the maximal tissue response to isoprenaline) were significantly higher in the uterus than in the right atrium.(ABSTRACT TRUNCATED AT 250 WORDS)[23]
  • 3. Absorption of oxprenolol occurred throughout the GI tract including the colon [24].

Associations of Coretal with other chemical compounds


Gene context of Coretal


Analytical, diagnostic and therapeutic context of Coretal


  1. A long-term prevention study with oxprenolol in coronary heart disease. Taylor, S.H., Silke, B., Ebbutt, A., Sutton, G.C., Prout, B.J., Burley, D.M. N. Engl. J. Med. (1982) [Pubmed]
  2. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. Thadani, U., Davidson, C., Singleton, W., Taylor, S.H. N. Engl. J. Med. (1979) [Pubmed]
  3. Heart-rates of surgeons during operations and other clinical activities and their modification by oxprenolol. Foster, G.E., Evans, D.F., Hardcastle, J.D. Lancet (1978) [Pubmed]
  4. Dose beta-blockade affect surgical performance? a double blind trial of oxprenolol. Foster, G.E., Makin, C., Evans, D.F., Hardcastle, J.D. The British journal of surgery. (1980) [Pubmed]
  5. Effect of oxprenolol on some fear-induced behavioral responses and hyperthermia in rats subjected to inescapable shocks. Noble, W., Delini-Stula, A. Psychopharmacology (Berl.) (1976) [Pubmed]
  6. The effects of diazepam and oxprenolol on short term memory in individuals of high and low state anxiety. Desai, N., Taylor-Davies, A., Barnett, D.B. British journal of clinical pharmacology. (1983) [Pubmed]
  7. Efficacy of four antihypertensive drugs (clonidine, enalapril, nitrendipine, oxprenolol) on stress blood pressure. Schmieder, R.E., Bähr, M., Langewitz, W., Rüddel, H., Schächinger, H., Schulte, W. Am. J. Cardiol. (1989) [Pubmed]
  8. Impact of antihypertensive therapy on blood pressure reactivity during mental stress. Rüddel, H., Schmieder, R., Langewitz, W., Schulte, W. Journal of human hypertension. (1988) [Pubmed]
  9. Thrombocytopenia due to slow-release oxprenolol. Dodds, W.N., Davidson, R.J. Lancet (1978) [Pubmed]
  10. Is the adrenergic control of renin release dominant in man? Davies, R., Slater, J.D. Lancet (1976) [Pubmed]
  11. Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Wilcox, R.G., Rowley, J.M., Hampton, J.R., Mitchell, J.R., Roland, J.M., Banks, D.C. Lancet (1980) [Pubmed]
  12. Intrinsic sympathomimetic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation. Raeder, E.A., Verrier, R.L., Lown, B. J. Am. Coll. Cardiol. (1983) [Pubmed]
  13. Increased plasma vasopressin in low renin essential hypertension. Os, I., Kjeldsen, S.E., Skjøtø, J., Westheim, A., Lande, K., Aakesson, I., Frederichsen, P., Leren, P., Hjermann, I., Eide, I.K. Hypertension (1986) [Pubmed]
  14. The effect of high dose oxprenolol on stress-induced physical and psychophysiological variables. Farhoumand, N., Harrison, J., Pare, C.M., Turner, P., Wynn, S. Psychopharmacology (Berl.) (1979) [Pubmed]
  15. Clinical pharmacology of pindolol. Aellig, W.H. Am. Heart J. (1982) [Pubmed]
  16. Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. Bolli, P., Bühler, F.R., Raeder, E.A., Amann, F.W., Meier, M., Rogg, H., Burckhardt, D. Circulation (1981) [Pubmed]
  17. Serotonergic and adrenergic regulation of skeletal muscle metabolism in the rat. II. The use of [125I]iodolysergic acid diethylamide and [125I]iodopindolol as probes of sarcolemmal receptor function and specificity. Moretti-Rojas, I., Ezrailson, E.G., Birnbaumer, L., Entman, M.L., Garber, A.J. J. Biol. Chem. (1983) [Pubmed]
  18. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial. Sassano, P., Chatellier, G., Billaud, E., Alhenc-Gelas, F., Corvol, P., Ménard, J. Am. J. Med. (1987) [Pubmed]
  19. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Laethem, M.E., Lefebvre, R.A., Belpaire, F.M., Vanhoe, H.L., Bogaert, M.G. Clin. Pharmacol. Ther. (1995) [Pubmed]
  20. Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. Fève, B., Emorine, L.J., Lasnier, F., Blin, N., Baude, B., Nahmias, C., Strosberg, A.D., Pairault, J. J. Biol. Chem. (1991) [Pubmed]
  21. Effect of beta receptor blockade on the initiation and perpetuation of ouabain-induced ventricular tachyarrhythmia. Apantaku, F.O., Baumgarten, C.M., Ten Eick, R.E. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  22. Concentration-dependent binding of the chiral beta-blocker oxprenolol to isoelectric or negatively charged unilamellar vesicles. Hellwich, U., Schubert, R. Biochem. Pharmacol. (1995) [Pubmed]
  23. The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Abrahamsson, T. Br. J. Pharmacol. (1986) [Pubmed]
  24. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. Davis, S.S., Washington, N., Parr, G.D., Short, A.H., John, V.A., Lloyd, P., Walker, S.M. British journal of clinical pharmacology. (1988) [Pubmed]
  25. Hemodynamic effects of oxprenolol and propranolol in hypertension. Franciosa, J.A., Johnson, S.M., Tobian, L.J. Clin. Pharmacol. Ther. (1979) [Pubmed]
  26. Atenolol and three nonselective beta-blockers in hypertension. Waal-Manning, H.J. Clin. Pharmacol. Ther. (1979) [Pubmed]
  27. Measurement of partial agonist activity of pindolol. Carruthers, S.G., Twum-Barima, Y. Clin. Pharmacol. Ther. (1981) [Pubmed]
  28. Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol. Jonkers, R., Van Boxtel, C.J., Oosterhuis, B. Clin. Pharmacol. Ther. (1987) [Pubmed]
  29. Regulation of interleukin-10 production by beta-adrenergic agonists. Suberville, S., Bellocq, A., Fouqueray, B., Philippe, C., Lantz, O., Perez, J., Baud, L. Eur. J. Immunol. (1996) [Pubmed]
  30. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Sekut, L., Champion, B.R., Page, K., Menius, J.A., Connolly, K.M. Clin. Exp. Immunol. (1995) [Pubmed]
  31. SKF 525A displaces drugs from serum alpha 1-acid glycoprotein binding sites. Belpaire, F.M., Chindavijak, B., Bogaert, M.G. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  32. Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Fraeyman, N.F., Dello, C.D., Belpaire, F.M. British journal of clinical pharmacology. (1988) [Pubmed]
  33. Determination of oxprenolol in plasma by column liquid chromatography. Devi, K.P., Rao, K.V., Baveja, S.K., Fathi, M., Roth, M. J. Chromatogr. (1988) [Pubmed]
  34. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Antonin, K.H., Bieck, P., Scheurlen, M., Jedrychowski, M., Malchow, H. British journal of clinical pharmacology. (1985) [Pubmed]
  35. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers. Woods, K.L., Jack, D.B., Kendall, M.J., Halsey, A., O'Donnell, M.L., Warrington, S.J., John, V.A. British journal of clinical pharmacology. (1985) [Pubmed]
  36. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects. Bradbrook, I.D., Babiker, M., Crome, P., Gillies, H.C., Morrison, P.J., Rogers, H.J., Shotton, P. British journal of clinical pharmacology. (1986) [Pubmed]
WikiGenes - Universities